NDAINTRAMUSCULARFOR SUSPENSION
Approved
Dec 2014
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
4/8 — Partial
SIGNIFOR LAR KIT (pasireotide) by Recordati is somatostatin receptor agonists [moa]. First approved in 2014.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SIGNIFOR LAR KIT is a long-acting intramuscular suspension of pasireotide, a somatostatin receptor agonist used to treat neuroendocrine and pituitary disorders. It works by binding to somatostatin receptors to suppress hormone secretion. The product targets patients with acromegaly, Cushing's disease, and neuroendocrine tumors requiring hormonal control.
LOE Approaching1.7 years to LOE
Product faces imminent loss of exclusivity with 1.7 years remaining; commercial team likely focused on defending market share and transitioning to managed decline.
Mechanism of Action
Somatostatin Receptor Agonists
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule
Started Dec 2025
40 enrolled
PharmacokineticsSafety
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
Started Dec 2024
28 enrolled
Desmoplastic Small Round Cell TumorSynovial Sarcoma
A Study of Pasireotide in People With Prolactinoma
Started Feb 2024
10 enrolled
Prolactin-Producing Pituitary Tumor
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Started Jan 2024
93 enrolled
Post-Bariatric Hypoglycemia
Pasireotide in Hyperinsulinemic Hypoglycemia
Started Apr 2017
0Congenital HyperinsulinismInsulinomaHyperinsulinism
Worked on SIGNIFOR LAR KIT at Recordati? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.